证券代码：002001 证券简称：新和成 公告编号：2025-009 浙江新和成股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、审议程序 浙江新和成股份有限公司（以下简称"公司"）于 2025 年 4 月 11 日召开的 第九届董事会第十一次会议审议通过《2024 年度利润分配预案》，该事项尚需提 交 2024 年年度股东大会审议。 二、2024 年度利润分配预案的基本情况 1、本次利润分配方案的基本内容 经天健会计师事务所（特殊普通合伙）审计，2024 年度公司实现净利润 5,896,870,207.59 元，其中归属于母公司股东的净利润 5,868,545,988.62 元。2024 年母公司实现净利润 2,726,593,387.44 元，加上年初未分配利润 5,137,599,917.63 元，减去 2024 年度分配股利 1,383,039,756.00 元，2024 年度提取盈余公积 0 元， 经决算，2024 年末可供股东分配的利润为 6,481,153,549.07 元。 若在分配方案实 ...

Financial Performance - The company's operating revenue for 2024 reached ¥21,609,592,228.45, representing a 42.95% increase compared to ¥15,116,537,003.30 in 2023[17]. - Net profit attributable to shareholders for 2024 was ¥5,868,545,988.62, a significant increase of 117.01% from ¥2,704,238,767.54 in 2023[17]. - The net profit after deducting non-recurring gains and losses was ¥5,828,938,494.33, up 122.97% from ¥2,614,210,640.58 in the previous year[17]. - Basic earnings per share for 2024 were ¥1.91, reflecting a 119.54% increase from ¥0.87 in 2023[17]. - The company's total assets at the end of 2024 amounted to ¥42,989,132,470.97, a 9.79% increase from ¥39,156,246,864.67 at the end of 2023[17]. - The net assets attributable to shareholders increased by 18.22% to ¥29,324,997,728.95 from ¥24,804,662,320.99 in 2023[17]. - Cash flow from operating activities for 2024 was ¥7,073,064,183.33, a 38.16% increase compared to ¥5,119,370,863.32 in 2023[17]. - The weighted average return on equity rose to 21.78%, an increase of 10.54 percentage points from 11.24% in 2023[17]. Revenue Breakdown - Revenue from the pharmaceutical and chemical sector accounted for ¥19.84 billion, which is 91.82% of total revenue, with a year-on-year growth of 43.81%[59]. - The nutrition products segment generated ¥15.05 billion, making up 69.67% of total revenue, with a significant increase of 52.58% compared to the previous year[59]. - The company’s total revenue for 2024 reached ¥21.61 billion, representing a 42.95% increase compared to ¥15.12 billion in 2023[59]. - The company achieved a 54.57% increase in foreign sales, amounting to ¥12.05 billion, which represents 55.78% of total revenue[59]. Market Outlook - The global demand for methionine is projected to increase by 6.3% in 2024, with domestic demand in China expected to rise by 4.7%[28][29]. - The vitamin market in China is expected to produce approximately 420,000 tons in 2024, accounting for 85.9% of global production, with prices recovering from a low point[27]. - The revenue of the fragrance and flavor industry in China is expected to reach ¥50 billion by 2025, with significant export contributions[30]. Research and Development - The company maintained R&D investment at over 5% of revenue for several consecutive years, focusing on key technologies with strategic economic impact[47]. - The company is focusing on expanding its core technology platforms in the fine chemical industry, particularly in nutrition, flavors, and new materials[26]. - The company is advancing the development of continuous reaction and pipeline reaction technologies to enhance production efficiency and competitiveness[72]. - The company has successfully achieved the production of vitamins B5 and B12 through optimized fermentation processes, positioning itself at the forefront of green manufacturing[72]. - R&D investment reached ¥1,036,161,740.50 in 2024, marking a 16.71% increase from ¥887,801,475.02 in 2023, while the ratio of R&D investment to operating revenue decreased by 1.08 percentage points to 4.79%[74]. Environmental Compliance - The company has established a comprehensive wastewater treatment system, ensuring effective collection and incineration of wastewater to reduce emissions[185]. - The company is committed to higher environmental standards and exploring eco-friendly production methods in response to evolving environmental regulations[115]. - The company has successfully renewed pollution discharge permits for multiple subsidiaries, valid until 2029[180]. - All reported pollutants from the companies were within the regulatory limits, indicating compliance with environmental standards[182]. Governance and Management - The company emphasizes compliance and transparent information disclosure, ensuring all shareholders have equal access to information[126]. - The company has a robust organizational structure with independent operational departments, ensuring no overlap with the controlling shareholder's functions[134]. - The company has appointed independent directors with diverse backgrounds, including expertise in economics, management, and law, enhancing governance[143]. - The company has a clear performance guidance strategy for the upcoming fiscal year[148]. Employee and Shareholder Relations - The company distributed a cash dividend of 4.50 RMB per 10 shares, totaling 1,383,039,756.00 RMB (including tax) based on a share base of 3,073,421,680 shares[163]. - The company has a competitive compensation structure that includes basic salary, performance pay, and benefits, aimed at enhancing employee satisfaction and loyalty[161]. - The total remuneration for directors, supervisors, and senior management amounted to CNY 31.62 million[153]. Strategic Initiatives - The company plans to accelerate its internationalization strategy and enhance local operational capabilities to navigate macroeconomic uncertainties[110]. - The company is considering strategic acquisitions to bolster its market position, with a budget of $200 million allocated for potential deals[117]. - The company aims to strengthen its nutrition business, focusing on integrated and market-coordinated operations to enhance product competitiveness[102].

Financial Performance - The company expects a net profit attributable to shareholders of 1.8 billion to 1.9 billion CNY for Q1 2025, representing a year-on-year increase of 107% to 118% compared to 869.62 million CNY in the same period last year [3]. - The net profit after deducting non-recurring gains and losses is also projected to be between 1.8 billion to 1.9 billion CNY, reflecting a growth of 110% to 122% from 857.47 million CNY in the previous year [3]. - Basic earnings per share are anticipated to be between 0.59 CNY and 0.62 CNY, up from 0.28 CNY per share in the same quarter last year [3]. Business Strategy - The increase in performance is attributed to higher sales volume and prices of key products in the nutrition segment compared to the previous year [5]. - The company will continue to focus on integrated, series, and collaborative development strategies, emphasizing "Chemical +" and "Biological +" main strategies [5]. - Future plans include enhancing application research and service capabilities, with a focus on nutrition products, flavors, high polymer new materials, and raw pharmaceutical materials [5]. - The company aims to strengthen its global marketing network and promote sustainable high-quality development while exploring opportunities in strategic emerging industries such as plant protection, new energy, energy conservation, and environmental protection [6]. Investment Risks - The financial data in the earnings forecast has not been audited by registered accountants, and investors are advised to pay attention to investment risks [4][7].

新和成（002001）公告，公司拟以自有资金或回购专项贷款以集中竞价交易的方式回购公司部分社会公 众股份，回购股份用于实施股权激励计划或员工持股计划。本次回购金额区间为3亿元-6亿元，回购价 格不超过人民币32元/股。按本次回购资金总额上下限人民币测算，预计回购股份区间为937.5万股-1875 万股，占公司总股本的比例区间为0.31%-0.61%。 ...

证券代码：002001 证券简称：新和成 公告编号：2025-010 浙江新和成股份有限公司 关于回购公司股份方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、浙江新和成股份有限公司（以下简称"公司"）第九届董事会第十一次 会议审议通过《关于回购公司股份方案的议案》，拟以自有资金或回购专项贷款 以集中竞价交易的方式回购公司部分社会公众股份，回购股份用于实施股权激励 计划或员工持股计划。本次回购金额区间为 30,000 万元-60,000 万元，回购价格 不超过人民币 32 元/股。按本次回购资金总额上下限人民币测算，预计回购股份 区间为 9,375,000 股-18,750,000 股，占公司总股本的比例区间为 0.31%-0.61%。 具体回购股份的数量以回购期满时实际回购的股份数量为准。本次回购股份期限 为自董事会审议通过本回购方案之日起 12 个月。 2、风险提示： （1）本次回购方案可能面临因回购期限内公司股票价格持续超出回购价格 上限等原因，导致本次回购方案无法实施或只能部分实施的风险。 （2）本次股份回购用于股权激励计 ...

据了解，中证浙江企业综合指数与中证浙江民营企业指数分别选取注册地在浙江省的全部上市公司证券 与民营上市公司证券作为指数样本，以反映浙江省上市公司证券和民营上市公司证券的整体表现。该指 数以2004年12月31日为基日，以1000.0点为基点。 金融界4月14日消息，上证指数高开高走，中证浙江民营企业指数 (浙江民企，000840)报7165.72点。 数据统计显示，中证浙江民营企业指数近一个月下跌12.68%，近三个月上涨3.32%，年至今下跌 1.28%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。特殊情况下将对指数进行临时调整。当样本退市时，将其从指数样本中剔除。样本公司发生收 购、合并、分拆等情形的处理，参照计算与维护细则处理。 从指数持仓来看，中证浙江民营企业指数十大权重分别为：同花顺（2.27%）、三花智控（2.22%）、 华友钴业（1.69%）、恒生电子（1.58%）、拓普集团（1.32%）、华东医药（1.31%）、新和成 （1.3%）、大华股份（1.23%）、中控技术（1.22%）、卫星化学（1.15%）。 从中证浙江民营企业指数持仓样 ...

Group 1 - The Shanghai Composite Index opened high and the CSI 300 Pharmaceutical and Biotechnology Index reported 7370.94 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has decreased by 1.33% in the past month, increased by 5.20% in the past three months, and decreased by 0.98% year-to-date [1] - The CSI 300 Index is categorized into 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] Group 2 - The top ten weights in the CSI 300 Pharmaceutical and Biotechnology Index are: Heng Rui Medicine (24.17%), WuXi AppTec (14.58%), Pian Zai Huang (6.92%), Yunnan Baiyao (5.68%), Kelun Pharmaceutical (5.11%), East China Pharmaceutical (3.63%), New Hope Liuhe (3.58%), Shanghai Raas (3.57%), Changchun High-tech (3.53%), and Fosun Pharma (3.39%) [1] - The market share of the CSI 300 Pharmaceutical and Biotechnology Index is 61.98% from the Shanghai Stock Exchange and 38.02% from the Shenzhen Stock Exchange [2] - The industry composition of the index includes: chemical drugs (42.08%), traditional Chinese medicine (20.00%), pharmaceutical and biotechnology services (19.84%), and biological drugs (18.08%) [2] Group 3 - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made when the CSI 300 Index samples are modified [2] - Special events affecting sample companies may lead to adjustments in the industry classification of the CSI 300 Industry Index [2]

Investment Rating - The report suggests a focus on sectors benefiting from import substitution, such as lubricant additives and nucleating agents, while also monitoring oil price stabilization for potential investment opportunities in oil-related assets [1][2][3]. Core Insights - The chemical market is experiencing pressure from trade conflicts, but the current market is more mature compared to 2018, with swift actions from the Chinese version of the stabilizing fund helping to restore market confidence [1][2]. - The report highlights significant downward pressure on industries with high exposure to the US market, particularly in consumer electronics and textiles, while sectors like lubricant additives and aramid fibers show strong performance due to import substitution [1][2]. - Key events include a notable drop in oil prices, with Brent crude falling below $60 per barrel, and the announcement of an expansion project by Wanhua Chemical [1][3]. Summary by Sections Market Overview - Brent crude futures averaged $64.12 per barrel this week, down 10.92% from the previous week, while WTI futures averaged $60.84 per barrel, down 11.4% [10]. - The basic chemical sector underperformed the index, with a decline of 5.14% [10]. Key Events - The establishment of a Chinese version of the stabilizing fund aims to bolster market confidence amid escalating trade tensions [2]. - The report notes a significant drop in oil prices due to trade war impacts and OPEC+ production increases, with Brent crude falling below $60 [2]. Industry Specific Insights - The tire industry is experiencing a slight decline in operating rates, with full steel tire operating rates at 66.2% and semi-steel tire rates at 78.5% [25]. - The sweetener market, particularly for sucralose, is expected to see price improvements due to reduced low-priced inventory and upcoming production cuts [26][27]. - The dye market remains stable, with disperse dyes maintaining prices around 16.5 yuan/kg, while demand from downstream textile markets is weak [28]. Price Trends - The report indicates that the average price for titanium dioxide is stable, with a market average of 15,109 yuan/ton, while the industry is observing a slight decline in operating rates [29]. - The pure MDI market is experiencing a downward trend, with prices averaging 17,350 yuan/ton, reflecting weak demand and ongoing trade tensions [32].

Group 1 - The company Xinhecheng has received approval for its isophorone diisocyanate (IPDI) project, with a planned capacity of 21,000 tons, and the first phase of the project has already been put into production [1] - The overall capacity planning for the HA project includes 103,000 tons of hexamethylene diisocyanate (HDI), 21,000 tons of IPDI, 20,000 tons of biuret, 83,000 tons of HDI trimer, 40,000 tons of isophorone diamine (IPDA), and by-products including 100,000 tons of hydrochloric acid and 6,400 tons of ammonium sulfate [1] - The first phase of the project includes the construction of production facilities for IPDA, HDI, IPDI, and biuret, supported by public utilities such as phosgene synthesis and CO₂ purification facilities, as well as environmental protection facilities [1] Group 2 - As of March 2025, products such as HDI, ADI, and IPDA have already been put into production, with annual capacities of 20,000 tons for IPDA, 4,000 tons for ADI, and 3,000 tons for HDI [2] - The domestic IPDI market reacted quickly to the supply disruption caused by the force majeure declarations from global chemical giants Evonik and Covestro, with prices rising from 34,000-38,000 yuan/ton to 35,000-39,000 yuan/ton, reflecting an average daily increase of approximately 1,000 yuan/ton [2] - IPDI is a cyclic diisocyanate that plays a significant role in water-based polyurethane applications and is widely used in plastics, adhesives, pharmaceuticals, and fragrances, indicating potential short-term market opportunities for domestic IPDI producers [2]

整体来看，新和成此次回购不仅有助于优化资本结构、提振市场信心，也进一步巩固了其作为全球维生 素行业领军者的地位。(厉平) 本次回购，体现出公司管理层对未来持续稳定发展的坚定信心，也有助于切实维护全体投资者的利益， 进一步增强市场信心。值得一提的是，控股股东新和成控股曾于2022年、2023年连续两次增持公司股 份，合计金额达6.88亿元，增持比例超过总股本的1%。此外，公司董事长胡柏藩及多位高管此前亦持 续增持公司股份，且从未减持，展现了对公司长期价值的高度认可。 4月8日，新和成（002001）发布公告称，公司实际控制人、董事长胡柏藩提议通过集中竞价交易方式回 购股份，回购资金总额在3亿元至6亿元之间。此次回购的股份将在未来适当时机用于股权激励或员工持 股计划，体现公司对员工的激励机制与"共享公司发展成果"理念的积极践行。 在国际环境方面，尽管近期美国推行"对等关税"政策，但新和成的主要维生素系列产品——包括VE、 VA、VC、VAD3、VB系列及辅酶Q10系列产品，均被列入豁免清单，不会对公司生产经营造成重大影 响。 新和成是全球领先的维生素生产企业之一，主营业务涵盖营养品、香精香料、高分子新材料和原料药 ...